Reza Dana, MD
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Reza Dana, MD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Reza Dana, MD: 5 sponsored US clinical trials, none currently recruiting.
Reza Dana, MD sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Corneal Graft Failure, with 1 trials.
Upper-quartile sponsor footprint
Reza Dana, MD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
NCT01996826
Treatment of Corneal Neovascularization With Topical Pazopanib
NCT01257750
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
NCT01072357
Topical IL-1-Ra for Treatment of Corneal Neovascularization
NCT00915590
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
NCT00681889
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
How the Reza Dana, MD early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Corneal Graft Failure (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Reza Dana, MD: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Reza Dana, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Reza Dana, MD page
5 registered trials is a research-attention snapshot, not an endorsement of Reza Dana, MD or any single study.
- None of Reza Dana, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Corneal Graft Failure is the condition Reza Dana, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Corneal Graft Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Reza Dana, MD pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.